These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 21266357)

  • 1. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.
    Qi J; McTigue MA; Rogers A; Lifshits E; Christensen JG; Jänne PA; Engelman JA
    Cancer Res; 2011 Feb; 71(3):1081-91. PubMed ID: 21266357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
    Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
    Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.
    Cepero V; Sierra JR; Corso S; Ghiso E; Casorzo L; Perera T; Comoglio PM; Giordano S
    Cancer Res; 2010 Oct; 70(19):7580-90. PubMed ID: 20841479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
    Ji F; Liu X; Wu Y; Fang X; Huang G
    Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.
    Nanjo S; Yamada T; Nishihara H; Takeuchi S; Sano T; Nakagawa T; Ishikawa D; Zhao L; Ebi H; Yasumoto K; Matsumoto K; Yano S
    PLoS One; 2013; 8(12):e84700. PubMed ID: 24386407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
    Okamoto W; Okamoto I; Yoshida T; Okamoto K; Takezawa K; Hatashita E; Yamada Y; Kuwata K; Arao T; Yanagihara K; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 May; 9(5):1188-97. PubMed ID: 20406949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
    Okamoto W; Okamoto I; Arao T; Kuwata K; Hatashita E; Yamaguchi H; Sakai K; Yanagihara K; Nishio K; Nakagawa K
    Mol Cancer Ther; 2012 Jul; 11(7):1557-64. PubMed ID: 22729845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.
    Corso S; Ghiso E; Cepero V; Sierra JR; Migliore C; Bertotti A; Trusolino L; Comoglio PM; Giordano S
    Mol Cancer; 2010 May; 9():121. PubMed ID: 20500904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
    Sugano T; Seike M; Noro R; Soeno C; Chiba M; Zou F; Nakamichi S; Nishijima N; Matsumoto M; Miyanaga A; Kubota K; Gemma A
    Mol Cancer Ther; 2015 Nov; 14(11):2433-40. PubMed ID: 26351321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
    Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
    J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
    Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
    Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.
    McDermott U; Pusapati RV; Christensen JG; Gray NS; Settleman J
    Cancer Res; 2010 Feb; 70(4):1625-34. PubMed ID: 20124471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
    Matsubara D; Ishikawa S; Oguni S; Aburatani H; Fukayama M; Niki T
    J Thorac Oncol; 2010 Sep; 5(9):1317-24. PubMed ID: 20736805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
    Christensen JG; Schreck R; Burrows J; Kuruganti P; Chan E; Le P; Chen J; Wang X; Ruslim L; Blake R; Lipson KE; Ramphal J; Do S; Cui JJ; Cherrington JM; Mendel DB
    Cancer Res; 2003 Nov; 63(21):7345-55. PubMed ID: 14612533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK inhibitors against MET-amplified non-small cell lung cancer.
    Chiba M; Togashi Y; Tomida S; Mizuuchi H; Nakamura Y; Banno E; Hayashi H; Terashima M; De Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
    Int J Oncol; 2016 Dec; 49(6):2236-2244. PubMed ID: 27748834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
    Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.
    Bachleitner-Hofmann T; Sun MY; Chen CT; Liska D; Zeng Z; Viale A; Olshen AB; Mittlboeck M; Christensen JG; Rosen N; Solit DB; Weiser MR
    Clin Cancer Res; 2011 Jan; 17(1):122-33. PubMed ID: 21208906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.